Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Lung Cancer Diagnosed Following a Negative CT Screening Examination

Principal Investigator
Name
David Gierada
Degrees
MD
Institution
Washington University
Position Title
Professor
Email
About this CDAS Project
Study
NLST (Learn more about this study)
Project ID
NLST-1
Initial CDAS Request Approval
Nov 15, 2012
Title
Lung Cancer Diagnosed Following a Negative CT Screening Examination
Summary
In the NLST, 44 of the 1060 (4.2%) participants in the CT arm were diagnosed with lung cancer within one year after a negative screening CT examination. Whether these cancers were present but overlooked or misinterpreted on the screening CT scan, or were new cancers that were new or not detectable by screening, is unknown. We will review these negative screening CT scans to make this distinction, and will compare the clinical features of these cancers to those detected through the screening process. This may help improve lung cancer detection on screening CT, and provide information on the nature of aggressive lung cancers.

Note: Prior work related to this project was done in <a href="/cdas/nlst/pubs_projects/project/458/">201112-0019</a>.
Aims

1. To retrospectively determine the frequency and characteristics of abnormalities suspicious for lung cancer on the last CT screen of NLST participants who had lung cancer diagnosed within a year of a negative screen

2. To determine whether each interval cancer had been overlooked on the CT (false negative) or was new or undetectable on the CT (interval cancer)

3. To assess the clinical outcomes of false negative and interval lung cancers in terms of stage, treatment, and mortality

Collaborators

Denise Aberle, MD UCLA
William Black, MD Dartmouth University
Fenhai Duan, PhD Brown University
Kavita Garg, MD University of Colorado
Eric Hart, MD Northwestern University
Subi Inampudi, MD Abbott Northwestern Hospital
Ella Kazerooni, MD University of Michigan
Paul Kvale, MD Henry Ford Hospital
Hrudaya Nath, MD University of Alabama
Paul Pinsky, PhD National Cancer Institute
Jubal Watts, MD University of Alabama
Carl Zylak, MD

Related Publications